IRVINE, Calif.--(BUSINESS WIRE)--Nov. 7, 2017--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development, and
commercialization of first-in-class therapies for the treatment of
patients with glaucoma and other diseases of the eye, today announced
that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer,
will present in a fireside chat discussion at the Stifel 2017 Healthcare
Conference on Tuesday, November 14, 2017 at 2:00 p.m. Eastern Time in
New York, NY. Dr. Anido will provide an Aerie overview and business
The fireside chat discussion will be webcast live and may be accessed by
visiting Aerie's website at http://investors.aeriepharma.com/.
A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two current product candidates are once-daily intraocular
pressure lowering therapies with novel mechanisms of action to treat
patients with glaucoma or ocular hypertension. The NDA (New Drug
Application) for Rhopressa™ (netarsudil ophthalmic solution) 0.02% was
submitted to the U.S. Food and Drug Administration (FDA) in February
2017, and, in May 2017, the FDA set the PDUFA (Prescription Drug User
Fee Act) goal date for the completion of the FDA’s review of the
Rhopressa™ NDA for February 28, 2018. Aerie’s second product candidate,
Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,
which is a fixed dose combination of Rhopressa™ and widely
prescribed PGA latanoprost, achieved its primary efficacy endpoint in
two Phase 3 registration trials, named Mercury 1 and Mercury 2, and also
achieved successful 12-month safety and efficacy results in Mercury 1.
The Roclatan™ NDA submission is expected to take place in the first half
of 2018. Aerie is also focused on global expansion and the development
of additional product candidates and technologies in ophthalmology.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171107005009/en/
Source: Aerie Pharmaceuticals, Inc.
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals